ANDA Bioequivalence Data Subject Of Upcoming FDA Proposed Rule
This article was originally published in The Tan Sheet
Executive Summary
FDA expects to issue an advance notice of proposed rulemaking in November requiring ANDA applicants to include data from all bioequivalence studies conducted on a drug formulation with their application
You may also be interested in...
AER Toll-Free Number Proposed Rule Targeted For September Release
The targeted action date for a proposed rule requiring the labeling of human drugs to carry a toll-free number for reporting adverse events has been pushed back to September, according to FDA's semi-annual "1unified agenda.
AER Toll-Free Number Proposed Rule Targeted For September Release
The targeted action date for a proposed rule requiring the labeling of human drugs to carry a toll-free number for reporting adverse events has been pushed back to September, according to FDA's semi-annual "1unified agenda.
AER Toll-Free Number Proposed Rule Targeted For September Release
The targeted action date for a proposed rule requiring the labeling of human drugs to carry a toll-free number for reporting adverse events has been pushed back to September, according to FDA's semi-annual "1unified agenda.